To compare visual acuity and refractive outcomes after Anwar's deep anterior lamellar keratoplasty (DALK) between eyes with and without successful big-bubble formation. In this retrospective comparative study, keratoconic eyes undergoing DALK with the big-bubble technique were divided into 2 groups: group 1 in which a bared Descemet membrane (DM) was achieved and group 2 in which layer-by-layer manual dissection was performed because of the lack of big-bubble formation after several intrastromal air injections. The 2 groups were compared with respect to best spectacle-corrected visual acuity, keratometric astigmatism, and refractive error at months 1, 3, 6, and 12, and at least 3 months after complete suture removal. A total of 123 keratoconic eyes were enrolled. A bared DM was successfully achieved in 100 eyes (81.3%) (group 1), whereas in 23 eyes (18.7%) (group 2), some posterior stroma was left in place. The mean follow-up period was 21 ± 9 months in group 1 and 23 ± 9 months in group 2 (P = 0.37). Postoperative best spectacle-corrected visual acuity was significantly better in group 1 than in group 2 at months 1, 3, 6, and 12. But, at the final examinations, there was no significant difference between the study groups (0.24 ± 0.21 logarithm of the minimum angle of resolution in group 1 and 0.32 ± 0.14 logarithm of the minimum angle of resolution in group 2; P = 0.18). The 2 groups were comparable regarding keratometric astigmatism and spherical equivalent refractive error throughout the follow-up period. Retention of posterior corneal stroma delayed visual recovery after DALK using Anwar's technique, but the participants in this group ultimately reached the same levels of visual acuity as observed in the bared-DM group.
1 May 2009 in Transactions of the Royal Society of Tropical Medicine and Hygiene
The stepwise implementation of the Tehran Sewerage Project provided a convenient setting for which health impacts of an urban sewerage system could be examined with appropriate controls. In 2001, Tehran municipal districts 17 and 18 had no sewerage system connections, but areas within these districts had been planned to be connected by 2006. These areas were chosen as an intervention group. Neighbouring areas, with a similar socio-economic status, that had not been planned to connect to the sewerage system by 2006, were chosen as controls. Homes within designated areas were randomized and surveyed twice to determine diarrhoea incidences for children aged 6–60 months, once in 2001, before connection to the sewerage system, and once again in 2006, after the intervention. By 2006, 76% of the homes in the intervention zones were connected to the sewerage system. In the first stage of the study, diarrhoea incidences for intervention and control groups were 18.6 and 16.6%, respectively. In the second stage, incidences decreased to 10.1 and 10.5%, respectively. Data collected from 4179 children demonstrated that the diarrhoea incidence had decreased by 46% in the intervention group, whereas it had decreased by 37% in the controls.
To evaluate the efficacy of 2% topical ciclosporin A in treating and preventing graft rejection episodes after penetrating keratoplasty (PKP) in patients with a history of graft rejection episodes. In this prospective, randomised, double-blind clinical trial, a group of PKP patients were randomly given 2% topical ciclosporin A (group 1) or a placebo (group 2) in addition to a corticosteroid regimen upon an episode of subepithelial or endothelial graft rejection. The topical ciclosporin and placebo were continued for 6 months. The duration of corticosteroid application and the time to resolution of the rejection episode for which ciclosporin or placebo was started, the number of concurrent and subsequent rejection episodes, and the rate of rejection-free survival were compared between the two groups. 22 eyes of 22 patients (12 men) were in group 1 and 21 eyes of 21 patients (10 men) were in group 2. Mean patient age was 32.48 (11.9 years and 35.48 (11.7 years in groups 1 and 2, respectively (p = 0.42). Mean follow-up period was 16.6 (6.1 months and 16.0 (6.3 months (p = 0.75) and the episode for which 2% topical ciclosporin or placebo was started completely resolved after 25.6 (21.0 days and 33.2 (16.7 days in groups 1 and 2, respectively (p = 0.22). The rejection-free graft survival rate was 34.8% in group 1 and 31.7% in group 2 at month 20 (p = 0.89). Conclusion 2% topical ciclosporin A did not add any advantage to conventional corticosteroid treatment in terms of treating and preventing graft rejection in PKP patients with previous history of rejection episodes.